HTLZF: AI 评分 53/100 — AI 分析 (4月 2026)

Hamilton Thorne Ltd. specializes in developing and distributing precision instruments, consumables, and software for the assisted reproductive technologies (ART), research, and cell biology markets. The company serves fertility clinics, hospitals, and research institutions across approximately 75 countries.

Key Facts: AI Score: 53/100 Sector: Healthcare

公司概况

概要：

Hamilton Thorne Ltd. provides advanced solutions for assisted reproductive technologies (ART), research, and cell biology, offering precision instruments, consumables, and software to a global network of fertility clinics, hospitals, and research institutions, with a focus on innovation and comprehensive ART solutions.

HTLZF是做什么的？

Hamilton Thorne Ltd., headquartered in Beverly, Massachusetts, develops, manufactures, and markets precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company's history is rooted in providing cutting-edge solutions for the ART field, evolving from precision laser systems to a comprehensive suite of products and services. Hamilton Thorne's offerings include precision laser systems, imaging systems, and other equipment and consumables under the Hamilton Thorne brand. Additionally, the company provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration, and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services under the Embryotech brand. The company also manufactures and distributes products for reproductive medicine, including clinical and laboratory equipment and disposables, as well as complete installations of ART clinics under the Gynemed brand. Furthermore, Hamilton Thorne offers bench top incubators, programmable freezers, loggers, alarms, cryo storage, and software systems and sensors for the safe preservation of medical and biological specimens used in ART and cell biology applications under the Planer brand. The company sells its products and services through a direct sales force in the United States, Germany, France, and the United Kingdom, as well as through distributors to approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries.

HTLZF的投资论点是什么？

Hamilton Thorne Ltd. presents a compelling investment case driven by the growing demand for assisted reproductive technologies and the company's comprehensive product portfolio. The company's focus on innovation and expansion into new markets, particularly in emerging economies, is expected to fuel revenue growth. A key value driver is the increasing adoption of advanced ART techniques, which require Hamilton Thorne's specialized equipment and software. The company's established distribution network and direct sales force in key markets provide a competitive advantage. However, the company's negative profit margin of -0.9% and high P/E ratio of -396.97 warrant careful consideration. Successful execution of growth strategies and improved profitability are crucial for realizing the company's long-term potential.

HTLZF在哪个行业运营？

Hamilton Thorne Ltd. operates within the assisted reproductive technology (ART) industry, a sector experiencing steady growth due to rising infertility rates, advancements in reproductive technologies, and increasing awareness of ART procedures. The global ART market is projected to reach billions of dollars by 2026, driven by factors such as delayed pregnancies, lifestyle changes, and medical conditions affecting fertility. The competitive landscape includes companies offering similar ART equipment, consumables, and services. Hamilton Thorne differentiates itself through its comprehensive product portfolio, global reach, and focus on innovation and customer service.

Medical - Devices

Healthcare

HTLZF有哪些增长机遇？

Expansion into Emerging Markets: Hamilton Thorne has the opportunity to expand its presence in emerging markets, where access to ART services is growing. These regions often have less competition and increasing demand for advanced reproductive technologies. By establishing strategic partnerships and distribution networks, Hamilton Thorne can capitalize on the growing ART market in countries with improving healthcare infrastructure. This expansion could contribute significantly to revenue growth over the next 3-5 years.
Development of New ART Technologies: Investing in research and development to create innovative ART technologies can drive future growth. This includes developing more advanced imaging systems, laser technologies, and software solutions for improving the success rates of ART procedures. By staying at the forefront of technological advancements, Hamilton Thorne can attract new customers and maintain its competitive edge. The timeline for realizing revenue from new technologies is approximately 2-4 years.
Strategic Acquisitions: Hamilton Thorne can pursue strategic acquisitions of complementary businesses to expand its product portfolio and market reach. Acquiring companies with expertise in specific areas of ART or cell biology can enhance Hamilton Thorne's offerings and create synergies. This strategy can accelerate growth and strengthen the company's position in the market. The timeline for integrating acquisitions and realizing their benefits is typically 1-3 years.
Increased Focus on Consumables: Consumables represent a recurring revenue stream for Hamilton Thorne. By expanding its range of consumables and increasing sales to existing customers, the company can generate stable and predictable revenue. This includes developing new and improved consumables for ART procedures and offering attractive pricing and service packages. The impact on revenue can be seen within 1-2 years.
Enhancing Software Solutions: Hamilton Thorne's software solutions play a crucial role in ART procedures. By continuously improving and expanding its software offerings, the company can provide added value to its customers and differentiate itself from competitors. This includes developing user-friendly interfaces, advanced data analytics tools, and seamless integration with other ART equipment. The timeline for developing and implementing new software features is approximately 6-18 months.

Market Cap of $0.25 billion reflects the company's current valuation in the assisted reproductive technology market.
Gross Margin of 50.4% indicates strong pricing power and efficient cost management in its product offerings.
The company serves approximately 2,000 fertility clinics, hospitals, pharmaceutical companies, biotechnology companies, educational institutions, and other commercial and academic research establishments in approximately 75 countries.
Beta of 0.41 suggests lower volatility compared to the overall market, potentially offering stability in investment portfolios.
Hamilton Thorne Ltd. operates in the growing ART market, driven by increasing infertility rates and advancements in reproductive technologies.

HTLZF提供哪些产品和服务？

Develops precision laser systems for assisted reproductive technologies (ART).
Manufactures imaging systems for cell biology research.
Offers consumables for ART procedures.
Provides software solutions for managing ART processes.
Distributes equipment and disposables for reproductive medicine.
Offers test laboratory and endotoxin testing services.
Supplies fresh and cryopreserved mouse embryos.
Provides technician training and proficiency testing services.

HTLZF如何赚钱？

Direct sales of precision instruments, consumables, and software to fertility clinics and research institutions.
Distribution through partners in approximately 75 countries.
Service contracts for maintenance and support of equipment.
Revenue from testing services and training programs.

Fertility clinics
Hospitals
Pharmaceutical companies
Biotechnology companies
Educational institutions
Commercial and academic research establishments

Specialized expertise in assisted reproductive technologies (ART).
Comprehensive product portfolio covering various aspects of ART and cell biology.
Established distribution network and direct sales force.
Strong brand reputation in the ART market.
Proprietary technologies and intellectual property.

什么因素可能推动HTLZF股价上涨？

Ongoing: Increasing global demand for assisted reproductive technologies (ART) due to rising infertility rates.
Upcoming: Potential regulatory approvals for new ART technologies and procedures.
Ongoing: Strategic partnerships and acquisitions to expand market reach and product portfolio.
Upcoming: Launch of new and improved software solutions for ART management.
Ongoing: Expansion into emerging markets with growing ART adoption rates.

HTLZF的主要风险是什么？

Potential: Competition from established and emerging ART equipment and service providers.
Potential: Regulatory changes affecting ART procedures and reimbursement rates.
Potential: Economic downturns impacting healthcare spending and ART adoption.
Ongoing: Negative profit margin and high P/E ratio.
Potential: Technological obsolescence and the need for continuous innovation.

HTLZF的核心优势是什么？

Comprehensive product portfolio for ART and cell biology.
Global distribution network and direct sales force.
Strong brand reputation in the ART market.
Expertise in precision instruments and software solutions.

HTLZF的劣势是什么？

Negative profit margin.
High P/E ratio.
Dependence on the ART market.
Limited presence in some emerging markets.

HTLZF有哪些机遇？

Expansion into new geographic markets.
Development of innovative ART technologies.
Strategic acquisitions of complementary businesses.
Increased focus on consumables and recurring revenue streams.

HTLZF面临哪些威胁？

Competition from other ART equipment and service providers.
Regulatory changes affecting ART procedures.
Economic downturns impacting healthcare spending.
Technological obsolescence.

HTLZF的竞争对手是谁？

Berna Biotech AG — Focuses on vaccine development and manufacturing. — (BRNHF)
biote Corp — Specializes in hormone optimization therapies. — (BTMD)
CSPC Pharmaceutical Group Ltd — Pharmaceutical company with a broad range of products. — (CSSPF)
DiaCarta Inc — Focuses on molecular diagnostics and precision medicine. — (DLHTF)
Eckert & Ziegler Strahlen- und Medizintechnik AG — Specializes in isotope technology for medical and industrial applications. — (EKDHF)

Key Metrics

MoonshotScore: 53/100

Company Profile

CEO: Ekaterina Torchilin MBA,
Headquarters: Beverly, US
Founded: 2010

AI Insight

AI analysis pending for HTLZF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hamilton Thorne Ltd. do?

Hamilton Thorne Ltd. specializes in developing, manufacturing, and distributing precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company's products are used in fertility clinics, hospitals, and research institutions worldwide to improve the success rates of ART procedures and advance scientific knowledge in reproductive biology. Hamilton Thorne's comprehensive product portfolio and global reach position it as a key player in the ART industry.

What do analysts say about HTLZF stock?

AI analysis is pending for HTLZF stock. Generally, analysts consider factors such as the company's revenue growth, profitability, market share, and competitive landscape when evaluating its potential. Key valuation metrics include the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio. Growth considerations include the company's ability to expand into new markets, develop innovative products, and maintain its competitive edge. A comprehensive analyst report would provide a more detailed assessment of HTLZF's investment prospects.

What are the main risks for HTLZF?

The main risks for Hamilton Thorne Ltd. include competition from other ART equipment and service providers, regulatory changes affecting ART procedures, economic downturns impacting healthcare spending, and technological obsolescence. The company's negative profit margin and high P/E ratio also pose financial risks. Additionally, the company's dependence on the ART market makes it vulnerable to changes in ART adoption rates and reimbursement policies. Effective risk management and mitigation strategies are crucial for Hamilton Thorne's long-term success.